LONDON, Oct. 7, 2015 /PRNewswire/ — Smith & Nephew (NYSE: SNN; LSE:SN), the global, medical technology business, today announced the launch of its TRIGEN META-TAN (Trochanteric Antegrade Nail) System at the Orthopaedic Trauma Association’s (OTA) annual meeting in San Diego. The META-TAN System expands the clinically proven TRIGEN Nail portfolio with a versatile design that addresses a wide range of femoral fractures ranging from specific hip fractures to mid-shaft fractures and fractures near the knee.
For hip fractures in patients with good bone quality, the META-TAN System features the company’s unique dual integrated screw design which is able to gain and maintain compression of the proximal femur. Additionally, the thinner size of the new nail may also benefit patients with narrow femoral canals.
For mid-shaft fractures and fractures near the knee, the variable bow of the nail provides versatile options for varying patient anatomy, and the multi-planar screw configuration allows for optimum fracture stability.
“High energy fractures in patients with good bone quality and less available space often pose challenges,” says Dr. Daniel Chan of Georgia Orthopaedic Trauma Institute. “META-TAN is an excellent solution as it does not require much bone removal with its smaller proximal body, while offering ‘recon’ compression capability when desired.”
Surgeons attending this week’s annual OTA meeting can learn more about the TRIGEN META-TAN System at the Smith & Nephew booth, #502.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 14,000 employees and a presence in more than 100 countries. Annual sales in 2014 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
